On December 14, 2018, Prestige Biopharma (“Prestige”) announced a partnership with Cipla Ltd. (“Cipla”) for Prestige’s HD201, a proposed trastuzumab biosimilar of Roche’s Herceptin^®.  Prestige’s HD201 is in Phase-3 clinical development for the treatment of patients with HER2-overexpressing breast cancer.

According to the press release, under the agreement, Cipla will have exclusive rights to distribute and market the drug in selected emerging markets.  Lisa S. Park, Prestige’s CEO, said “[w]ith this partnership, we made another important step towards a broad global availability of our Trastuzumab biosimilar product.”